NSRX (Nasus Pharma Ltd.) Stock Analysis - Analyst Ratings

Nasus Pharma Ltd. (NSRX) is a publicly traded the market company. As of May 21, 2026, NSRX trades at $2.74 with a market cap of $32.20M and a P/E ratio of 0.00. NSRX moved +2.20% today. Year to date, NSRX is -70.05%; over the trailing twelve months it is flat. Its 52-week range spans $1.98 to $9.99. Analyst consensus is buy with an average price target of $18.00. Rallies surfaces NSRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate NSRX?

1 analysts cover NSRX: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $18.00.

NSRX Key Metrics

Key financial metrics for NSRX
MetricValue
Price$2.74
Market Cap$32.20M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$9.99
52-Week Low$1.98
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

NSRX Analyst Consensus

1 analysts cover NSRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.00.

Latest NSRX News

Recent NSRX Insider Trades

  • Teleman Dan Benjamin bought 2.90K (~$10.90K) on Apr 22, 2026.
  • Teleman Dan Benjamin bought 15.00K (~$30.60K) on Mar 31, 2026.

Common questions about NSRX

What do analysts rate NSRX?
1 analysts cover NSRX: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $18.00.
Does Rallies show NSRX price targets?
Yes. Rallies tracks NSRX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is NSRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NSRX. It does not provide personalized investment advice.
NSRX

NSRX